MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04498nam a22005657a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220511s20222022 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0028-4793 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1056/NEJMoa2119657 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC9006786 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
35353960 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Early Outpatient Treatment for Covid-19 with Convalescent Plasma. |
| 251 ## - Source |
|---|
| Source |
New England Journal of Medicine. 386(18):1700-1711, 2022 05 05. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
N Engl J Med. 386(18):1700-1711, 2022 05 05. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
N Engl J Med. 2022 Mar 30 |
| 253 ## - Journal Name |
|---|
| Journal name |
The New England journal of medicine |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2022 Mar 30 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2022-05-11 |
| 268 ## - Previous citation |
|---|
| -- |
New England Journal of Medicine. 2022 Mar 30 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
BACKGROUND: Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: In participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization. (Funded by the Department of Defense and others; CSSC-004 ClinicalTrials.gov number, NCT04373460.). Copyright ♭ 2022 Massachusetts Medical Society. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: In this multicenter, double-blind, randomized, controlled trial, we evaluated the efficacy and safety of Covid-19 convalescent plasma, as compared with control plasma, in symptomatic adults (>=18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status. Participants were enrolled within 8 days after symptom onset and received a transfusion within 1 day after randomization. The primary outcome was Covid-19-related hospitalization within 28 days after transfusion. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: Participants were enrolled from June 3, 2020, through October 1, 2021. A total of 1225 participants underwent randomization, and 1181 received a transfusion. In the prespecified modified intention-to-treat analysis that included only participants who received a transfusion, the primary outcome occurred in 17 of 592 participants (2.9%) who received convalescent plasma and 37 of 589 participants (6.3%) who received control plasma (absolute risk reduction, 3.4 percentage points; 95% confidence interval, 1.0 to 5.8; P = 0.005), which corresponded to a relative risk reduction of 54%. Evidence of efficacy in vaccinated participants cannot be inferred from these data because 53 of the 54 participants with Covid-19 who were hospitalized were unvaccinated and 1 participant was partially vaccinated. A total of 16 grade 3 or 4 adverse events (7 in the convalescent-plasma group and 9 in the control-plasma group) occurred in participants who were not hospitalized. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*COVID-19 |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Immunization, Passive |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Adult |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Ambulatory Care |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19/th [Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Disease Progression |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Double-Blind Method |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hospitalization |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunization, Passive |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunization, Passive/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunization, Passive/mt [Methods] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Outpatients |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmaceutical Preparations |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
United States |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Shenoy, Aarthi |
| 790 ## - Authors |
|---|
| All authors |
Abinante M, Anjan S, Appel LJ, Baksh SN, Blair JE, Bloch EM, Broderick PB, Cachay ER, Casadevall A, Cluzet VC, Cordisco ME, Cruser D, Currier JS, Ehrhardt S, Ford DE, Forthal DN, Foster EC, Fukuta Y, Gawad AL, Gebo KA, Gerber JM, Gniadek TJ, Greenblatt B, Hammel J, Hammitt LL, Hanley DF, Heath SL, Huaman MA, Jabs DA, Karlen N, Kassaye SG, Klein SL, Laeyendecker O, Lane K, Lau B, Levine AC, Marshall CE, McBee NA, Meisenberg BR, Mosnaim GS, Oei K, Patel B, Paxton JH, Pekosz A, Petrini JR, Rausch W, Raval JS, Roth M, Shade DM, Shenoy AG, Shoham S, Singh A, Spivak ES, Sullivan DJ, Sutcliffe CG, Tobian AAR, Yarava A, Zand MS |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1056/NEJMoa2119657">https://dx.doi.org/10.1056/NEJMoa2119657</a> |
| Public note |
https://dx.doi.org/10.1056/NEJMoa2119657 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
